Does CABOZANTINIB S-MALATE Cause Inappropriate schedule of product administration? 1,656 Reports in FDA Database

Q: Does CABOZANTINIB S-MALATE cause Inappropriate schedule of product administration?

1,656 reports of Inappropriate schedule of product administration have been filed with the FDA for CABOZANTINIB S-MALATE, representing 4.2% of all CABOZANTINIB S-MALATE adverse event reports.

Q: How dangerous is Inappropriate schedule of product administration from CABOZANTINIB S-MALATE?

Of 1,656 reports, 65 (3.9%) resulted in death and 212 required hospitalization.

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,656 reports of Inappropriate schedule of product administration have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 4.2% of all adverse event reports for CABOZANTINIB S-MALATE.

1,656

Reports of Inappropriate schedule of product administration with CABOZANTINIB S-MALATE

4.2%

of all CABOZANTINIB S-MALATE reports

Deaths

212

Hospitalizations

How Dangerous Is Inappropriate schedule of product administration From CABOZANTINIB S-MALATE?

Of the 1,656 reports, 65 (3.9%) resulted in death, 212 (12.8%) required hospitalization, and 10 (0.6%) were considered life-threatening.

Is Inappropriate schedule of product administration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 1,656 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Inappropriate schedule of product administration?

ADAPALENE (16,473) DUPILUMAB (14,927) AVOBENZONE\OCTISALATE\OCTOCRYLENE (12,546) INSULIN GLARGINE (8,982) INFLIXIMAB (6,847) INFLIXIMAB-DYYB (5,977) SECUKINUMAB (4,817) DULAGLUTIDE (3,606) VEDOLIZUMAB (3,259) SACUBITRIL\VALSARTAN (2,870)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Inappropriate schedule of product administration Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

CABOZANTINIB S-MALATE Full Profile All Inappropriate schedule of product administration Reports All Drugs Causing Inappropriate schedule of product administration CABOZANTINIB S-MALATE Demographics